

# CAMCEVI® (leuprolide mesylate) 42 mg Prolonged-Release Suspension for Injection A Ready-to-Use Pre-Filled Syringe


This promotional infographic was supported and funded by Accord Healthcare Ltd and is intended for HCPs only.

**UK Prescribing Information for CAMCEVI 42mg can be found [here](#).**  
**EU SmPC for CAMCEVI 42mg plus Legal Category can be found [here](#).**


There are extended indications for CAMCEVI® (leuprolide) 42 mg in the UK. UK HCPs should refer to either the UK SmPC or UK prescribing information for further details.

Always consult local prescribing information in the country of practice as information may vary. Adverse Events Reporting information can be found at the bottom of this infographic.

**CAMCEVI® (leuprolide mesylate) 42 mg offers a simplified preparation ADT with its pre-filled, ready-to-use syringe for convenient subcutaneous administration every 6 months.**



Remove CAMCEVI® kit from refrigerator, allow 15–30 minutes to reach room temperature, then inspect syringe and needle for damage or particles before use.<sup>1</sup>



Remove the gray cap from the syringe (A). Attach the needle (B) to the end of the syringe (A) by pushing and turning clockwise with approximately a threequarter turn until the needle is secure. Do not over-tighten. Discard pre-filled CAMCEVI syringe if over-twist causes syringe breakage.



Select an appropriate injection site on the abdomen with sufficient subcutaneous tissue, that has not been used as an injection site recently.<sup>1</sup>




Clean the injection site, insert the needle at 90°, inject the full dose slowly, then withdraw the needle.<sup>1</sup>

Please see Summary of Product Characteristics for full preparation and administration instructions.

- ADT suppresses androgens to control advanced prostate cancer.<sup>1</sup>
- CAMCEVI® enables the efficient delivery of ADT.<sup>1</sup>
- The multicentre, single-arm, open-label, 48-week phase 3 study of leuprorelin included 137 male patients with high-risk localised and locally advanced prostate cancer in need for androgen deprivation therapy.<sup>1</sup>
- 98.5% of patients who received CAMCEVI® 42mg achieved and maintained castrate levels\* of testosterone by Day 28 (95% CI, 94.8–99.8) and 97% of patients maintained castrate levels from Day 28–336 (95% CI, 92.2–98.9).<sup>1,2</sup>
- 86.4% of patients (n=76/88) of patients achieved PSA ≤ 4ng/mL on Day 336.<sup>1,2</sup>


\*Castrate testosterone levels were defined as ≤50ng/dL.<sup>2</sup> †ITT population receiving at least 1 dose.<sup>2</sup>  
<sup>2</sup>In a post-hoc analysis of 99 patients who had elevated PSA (>4 ng/mL) at baseline.<sup>2</sup>

## Mean serum testosterone over time ITT population<sup>2</sup>



Adapted from Shore et al.<sup>2</sup>

## Assembled pre-filled syringe:<sup>1</sup>



Images not to scale.



Sterile, pre-filled syringe minimises contamination and allergy risk.<sup>1</sup>



Refrigerate at 2–8 °C; 2-year shelf life.<sup>1</sup>



Very common side effects include hot flashes, ecchymoses, erythema, fatigue, injection site burning, injection site paraesthesia and malaise.<sup>1</sup>

Please see SmPC for full adverse drug reactions.



Monitor metabolic and cardiovascular risks during long-term ADT.<sup>1</sup>

## Key Takeaways:

Ready-to-use CAMCEVI® streamlines ADT administration, minimising steps and errors.

- Long-term hormone suppression for prostate cancer<sup>1</sup>
- Direct subcutaneous use; no mixing required<sup>1</sup>
- Robust clinical evidence and regulatory approval<sup>1</sup>
- Reduces preparation and wait times
- Standardises ADT care across settings



Images not to scale.

**Adverse events should be reported.** For UK HCPs, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Accord LTD on +44 (0)1271 385 257 or email [medinfo@accord-healthcare.com](mailto:medinfo@accord-healthcare.com). For non-UK/EU HCPs, you can also report side effects directly via the national reporting system listed in Appendix V of the EU SmPC.

**Abbreviations:** ADT: androgen deprivation therapy; PSA: prostate-specific antigen.

## References:

1. Camcevi. Summary of product characteristics. Available at: [https://www.emjreviews.com/wp-content/uploads/2026/01/CAMCEVI\\_EU-SmPC-Legal-Classification-1.pdf](https://www.emjreviews.com/wp-content/uploads/2026/01/CAMCEVI_EU-SmPC-Legal-Classification-1.pdf). Last accessed: 7 April 2026.
2. Shore N et al. World J Urol. 2020;38(1):111–19.